Zobrazeno 1 - 10
of 114
pro vyhledávání: '"Øystein Rekdal"'
Autor:
Morten Nielsen, Tine Monberg, Vibeke Sundvold, Benedetta Albieri, Dorrit Hovgaard, Michael Mørk Petersen, Anders Krarup-Hansen, Özcan Met, Ketil Camilio, Trevor Clancy, Richard Stratford, Baldur Sveinbjornsson, Øystein Rekdal, Niels Junker, Inge Marie Svane
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
ABSTRACTLTX-315 is an oncolytic peptide that elicits both local and systemic immune responses upon intratumoral injection. In the present pilot trial, we treated patients with metastatic soft tissue sarcoma with the combination of LTX-315 and adoptiv
Externí odkaz:
https://doaj.org/article/be8b6380d15946d0be5185169cae65f6
Autor:
Xiao-Qing Li, Takahiro Yamazaki, Tianzhen He, Md Masud Alam, Jia Liu, Anna L. Trivett, Baldur Sveinbjørnsson, Øystein Rekdal, Lorenzo Galluzzi, Joost J. Oppenheim, De Yang
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
LTX-315 is a synthetic cationic oncolytic peptide with potent anticancer activity but limited toxicity for non-malignant cells. LTX-315 induces both immunogenic tumor cell death and generation of tumor-specific immune responses in multiple experiment
Externí odkaz:
https://doaj.org/article/38be6eb6a7bf4036a60a9ac668042e62
Autor:
Karianne Giller Fleten, J. Johannes Eksteen, Brynjar Mauseth, Ketil André Camilio, Terje Vasskog, Baldur Sveinbjørnsson, Øystein Rekdal, Gunhild M. Mælandsmo, Kjersti Flatmark
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract Oncolytic peptides represent a novel, promising cancer treatment strategy with activity in a broad spectrum of cancer entities, including colorectal cancer (CRC). Cancer cells are killed by immunogenic cell death, causing long-lasting antica
Externí odkaz:
https://doaj.org/article/c4650db71ccd45e48578b7112001c09e
Autor:
Kamal S. Saini, Begoña de las Heras, Ruth Plummer, Victor Moreno, Marco Romano, Javier de Castro, Philippe Aftimos, Judy Fredriksson, Gouri Shankar Bhattacharyya, Martin Sebastian Olivo, Gaia Schiavon, Kevin Punie, Jesus Garcia-Foncillas, Ernesto Rogata, Richie Pfeiffer, Cecilia Orbegoso, Kenneth Morrison, Giuseppe Curigliano, Lynda Chin, Monika Lamba Saini, Øystein Rekdal, Steven Anderson, Javier Cortes, Manuela Leone, Janet Dancey, Chris Twelves, Ahmad Awada
Publikováno v:
JCO Global Oncology, Vol , Iss 6, Pp 1357-1362 (2020)
Externí odkaz:
https://doaj.org/article/e753a4f9fda043498869674261249653
Publikováno v:
ACS Omega, Vol 5, Iss 10, Pp 4937-4942 (2020)
Externí odkaz:
https://doaj.org/article/099f4ba8cfb34c12833077bb700e12b6
Autor:
Hsin-Wei Liao, Christopher Garris, Christina Pfirschke, Steffen Rickelt, Sean Arlauckas, Marie Siwicki, Rainer H. Kohler, Ralph Weissleder, Vibeke Sundvold-Gjerstad, Baldur Sveinbjørnsson, Øystein Rekdal, Mikael J. Pittet
Publikováno v:
Cell Stress, Vol 3, Iss 11, Pp 348-360 (2019)
LTX-315 is an oncolytic peptide that has antitumor efficacy in mice grafted with various tumor cell lines and is currently being tested in phase II clinical trials. Here we aimed to further evaluate LTX-315 in conditional genetic mouse models of canc
Externí odkaz:
https://doaj.org/article/3c2d5b260fbe4adb94f8a76380519ac6
Autor:
Brynjar Mauseth, Ketil André Camilio, Jihua Shi, Clara Louise Hammarström, Øystein Rekdal, Baldur Sveinbjørnsson, Pål-Dag Line
Publikováno v:
Molecular Therapy: Oncolytics, Vol 14, Iss , Pp 139-148 (2019)
LTX-401 is a novel oncolytic compound designed for the local treatment of solid tumors. In the present study, we have examined the applicability and efficacy of LTX-401 in a rat model JM1 hepatocellular carcinoma, with particular interest in its abil
Externí odkaz:
https://doaj.org/article/c2d41844b96b48f49502b5cc600385b1
Autor:
Nina Louise Jebsen, Torunn Oveland Apelseth, Hans Kristian Haugland, Øystein Rekdal, Hamina Patel, Bjørn Tore Gjertsen, Dag Eirik Jøssang
Publikováno v:
Journal of Medical Case Reports, Vol 13, Iss 1, Pp 1-9 (2019)
Abstract Background Desmoid tumors are intermediary malignant, fibrous lesions occurring in various soft tissues. Surgical treatment is relentlessly challenging because of the propensity for local aggressive behavior and high risk of recurrence. Cons
Externí odkaz:
https://doaj.org/article/91d523716cd244b5bd30a460aaad9a49
Autor:
Ketil A. Camilio, Meng-Yu Wang, Brynjar Mauseth, Stein Waagene, Gunnar Kvalheim, Øystein Rekdal, Baldur Sveinbjørnsson, Gunhild M. Mælandsmo
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-12 (2019)
Abstract Background Immunochemotherapy, the combined use of immunotherapy and chemotherapy, has demonstrated great promise in several cancers. LTX-315 is an oncolytic peptide with potent immunomodulatory properties designed for the local treatment of
Externí odkaz:
https://doaj.org/article/638eb6cee08a48ca8c27c37a1050bc02
Autor:
Takahiro Yamazaki, Erik Wennerberg, Michal Hensler, Aitziber Buqué, Jeffrey Kraynak, Jitka Fucikova, Xi Kathy Zhou, Baldur Sveinbjørnsson, Øystein Rekdal, Sandra Demaria, Lorenzo Galluzzi
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
LTX-315 is a nonameric oncolytic peptide in early clinical development for the treatment of solid malignancies. Preclinical and clinical evidence indicates that the anticancer properties of LTX-315 originate not only from its ability to selectively k
Externí odkaz:
https://doaj.org/article/26e51e80d5d54275a28570327a2e04cd